NAmur Research Institute for LIfe Sciences
Ken Kudura
Nuclear medicine
Prof. Ken Kudura MD, PhD
Prof. Ken Kudura MD, PhDCHU UCL Namur, Site Godinne, Department of Nuclear medicine
Member of Institute of Experimental and Clinical Research (IREC), UCLouvain
ORCID | ResearchGate | LinkedIn
Expertise and research interests
Ken Kudura is a nuclear medicine physician and radiologist, currently Professor of Nuclear Medicine at the UCLouvain and Head of the Nuclear Medicine Department at CHU UCL Namur - Godinne.
He earned his medical degree from the University of Cologne and completed his specialist training in radiology and nuclear medicine at Helios Hospital Berlin (2014 to 2017) and at the University Hospital Zurich (2017 to 2020). From 2021 to 2024, he served as a senior physician in nuclear medicine and radiology at Clarunis - University Abdominal Centre Basel (2021-2024), before joining the CHU UCL Namur in September 2024.
In addition to his academic and clinical roles, Ken Kudura was elected to the Board of the Belgian Society of Nuclear Medicine in 2025, and as Honorary Member of the Congolese Society of Radiology in 2024.
His scientific interests include:
- Oncological imaging (outcome prediction models with different segmentation methods and radiotracers)
- Immunotherapies
- Cardiac imaging/Gender medicine
- Theranostics
Research projects
Selected publications
Kudura K, Ritz N, Templeton AJ, Kutzker T, Hoffmann MHK, Antwi K, Zwahlen DR, Kreissl MC, Foerster R. An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data. Cancers (Basel). 2023 Nov 20;15(22):5476.
Kudura K, Ritz N, Templeton AJ, Kutzker T, Foerster R, Antwi K, Kreissl MC, Hoffmann MHK. Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition. J Clin Med. 2023 May 28;12(11):3725.
Kudura K, Ritz N, Templeton AJ, Kissling M, Kutzker T, Foerster R, Hoffmann MHK, Antwi K, Kreissl MC. Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival. Cancers (Basel). 2023 Feb 28;15(5):1521.
Kudura K, Ritz N, Kutzker T, Hoffmann MHK, Templeton AJ, Foerster R, Kreissl MC, Antwi K. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. Cancers (Basel). 2022 Dec 11;14(24):6095.
Kudura K, Basler L, Nussbaumer L, Foerster R. Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition. Cancers (Basel). 2022 Oct 20;14(20):5145.
Kudura K, Nussbaumer L, Foerster R, Basler L. Inflammatory Blood Parameters as Biomarkers for Response to Immune Checkpoint Inhibition in Metastatic Melanoma Patients. Biomedicines. 2022 Aug 31;10(9):2135.
Kudura K, Kern B, Hoffmann MHK, Antwi K. The use of 18F-Choline-PET/CT in chronic lymphocytic leukaemia. J Clin Images Med Case Rep. 2022; 3(4): 1781.
Kudura K, Dimitriou F, Basler L, Förster R, Mihic-Probst D, Kutzker T, Dummer R, Mangana J, Burger IA, Kreissl MC. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers (Basel). 2021 Jul 29;13(15):3830.
Kudura K, Dimitriou F, Mihic-Probst D, Muehlematter UJ, Kutzker T, Basler L, Förster R, Dummer R, Mangana J, Husmann L, Burger IA, Kreissl MC. Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients. Diagnostics (Basel). 2021 May 15;11(5):883.
Kudura K, Oblasser T, Ferraro DA, Mader CE, Husmann L, Friedrich K, Ter Voert EEGW, Burger IA. Metal artifact reduction in 68Ga-PSMA-11 PET/MRI for prostate cancer patients with hip joint replacement using multiacquisition variable-resonance image combination. Eur J Hybrid Imaging. 2020 Apr 9;4(1):6.
